Harbor Capital Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Harbor Capital Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-67,642	Closed	-$101K	–	666
2023 Q1	$101K	Sell	67,642 -588	-0.9%	-$792	0.03%	237
2022 Q4	$68.1K	Sell	68,230 -1,453	-2%	-$1.96K	0.07%	152
2022 Q3	$125K	Buy	69,683 +5,342	+8%	+$15.5K	0.11%	83
2022 Q2	$187K	Sell	64,341 -3,222	-5%	-$7.95K	0.14%	83
2022 Q1	$186K	Sell	67,563 -16,056	-19%	-$50.5K	0.09%	92
2021 Q4	$390K	Buy	+83,619	New	+$523K	0.14%	89

Harbor Capital Advisors's TCRR Position: Q2 2023 in Review

Harbor Capital Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 67,642 shares — an estimated $101K sold.

Harbor Capital Advisors first reported a position in TCRR in Q4 2021 and held it in 6 quarters. The position peaked at $390K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Harbor Capital Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Harbor Capital Advisors sold 67,642 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $101K.
Harbor Capital Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Harbor Capital Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $390K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Harbor Capital Advisors's 13F filing for Q2 2023, filed 11 Jul 2023.